3-三氟甲氧基苯乙炔 | 866683-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-三氟甲氧基苯乙炔
• 中文别名: 1-乙炔基-3-(三氟甲氧基)苯；3-(三氟甲氧基)苯基乙炔
• 英文名称: 1-ethynyl-3-(trifluoromethoxy)benzene
• CAS: 866683-57-0
• 化学式: C₉H₅F₃O
• 分子量: 186.133
• InChiKey: NWBWKSOPVZODSM-UHFFFAOYSA-N

物化性质

• 沸点：
  166.3±40.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2909309090
• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P210,P233,P240,P241,P242,P243,P260,P261,P264,P271,P280,P302+P352,P303+P361+P353,P304,P304+P340,P305+P351+P338,P312,P321,P332+P313,P337+P313,P340,P362,P370+P378,P403,P403+P233,P403+P235,P405,P501
• 危险品运输编号：
  1993
• 危险性描述：
  H225,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Ethynyl-3-(trifluoromethoxy)-benzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Ethynyl-3-(trifluoromethoxy)-benzene
CAS number: 866683-57-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H5F3O
Molecular weight: 186.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴烟腈 、 3-三氟甲氧基苯乙炔 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 三乙胺 作用下， 以 乙酸乙酯 为溶剂， 反应 18.0h， 以15%的产率得到5-(3-trifluoromethoxyphenylethynyl)-nicotinonitrile
  参考文献：
  名称：

  [EN] PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS
  [FR] DERIVES DE PYRIDYLE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RECEPTEUR DE MGLU5

  摘要：

  本发明涉及公式（I）的吡啶衍生物作为mGlu5受体拮抗剂。因此，这些化合物可能对通过拮抗mGlu5受体而得到缓解的疾病的治疗或预防有用，其中Ar是苯基或萘基，每种基可能被一个或多个C1-C4烷基，C1-C4烷氧基，C1-C5酰基，卤素，氨基，硝基，氰基，羟基，C1-C5酰胺基，C1-C4烷基磺酰胺基，单-，二-或三氟代的C1-C3烷基，取代基可能相同也可能不同，并且可能带有CONH2，CONHCH3，CON(CH3)2，CO2H，CO2CH3，OCF3，CH2NHCOCH3，CH2NH2，CH2N(CH3)2，CH2CN，CH2OH，CH2NHSO2CH3，CH2N(CH3)(CH2)2CN，CH2N(CH3)CH(CH3)2，CH2NHCH(CH3)2，CH2NH(CH2)2CH3，CH2NHCO2R4，CH2NHCH2CH3，CH2NHCH3 NHCOC(CH3)2或N(S(O)2CH3)2取代基；R1是氢，卤素，R4，CN，C(NOH)R3，C(NO-R4)R3，(CH)2CO2R4，(CH2)nOR3，COR3，CF3，SR4，S(O)R4，S(O)2R4，COCH2CO2R3，NHSO2R4，NHCOR3，C(NOR3)NH2，CH2OCOR3，(CH2)nNH2，CON(CH3)2(CH2)nNHCO2R4，CO2R3，CONH2，CSNH2，C(NH)NHOR3，(CH2)nN(CH3)2或CONHNHCOR3；R2是1,2-乙烯二基或1,2-乙炔二基；R3是氢或C1-C4烷基；R4是C1-C4烷基；n为0,1,2,3或4；或其药学上可接受的盐，或其N-氧化物。

  公开号：

  WO2005094822A1
• 作为产物：
  描述：

  trimethyl-(3-trifluoromethoxyphenylethynyl)-silane 在 甲醇 、 potassium carbonate 作用下， 生成 3-三氟甲氧基苯乙炔
  参考文献：
  名称：

  电化学金催化 C−C 多重键的 1,2-双官能化**

  摘要：

  第一份关于电化学 Au I /Au III催化 C−C 多重键 1,2-双官能化的报告已经发表。这种无外部氧化剂的方法利用乙烯基-Au I到乙烯基-Au III络合物的阳极氧化来实现联烯酸酯的氧炔化，从而在未分裂的电池中获得炔取代的丁烯内酯。

  DOI：

  10.1002/anie.202308636

文献信息

• [EN] PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS<br/>[FR] COMPOSÉS DE PYRIDAZINONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA DAAO
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013027000A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物及其药用盐，其中R1和R2如规范中定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• Palladium-Catalyzed Ligand-Free Double Cyclization Reactions for the Synthesis of 3-(1′-Indolyl)-phthalides
  作者：Shuo Yuan、Dan-Qing Zhang、Jing-Ya Zhang、Bin Yu、Hong-Min Liu

  DOI：10.1021/acs.orglett.9b04241

  日期：2020.2.7

  heterocyclic scaffolds in numerous natural products and bioactive molecules. The synthesis and biological evaluation of the compounds combining these two scaffolds have rarely been reported. Herein, we repot the first palladium-catalyzed ligand-free double cyclization reactions that enable efficient synthesis of 3-(1'-indolyl)-phthalides (42 examples, up to 96% yield) under mild conditions. Notably

  吲哚和邻苯二甲酸酯是众多天然产物和生物活性分子中的特权杂环骨架。很少有报道结合这两种支架的化合物的合成和生物学评估。在这里，我们提出了第一个无钯催化的无配体双环化反应，该反应能够在温和条件下有效合成3-（1'-吲哚基）-邻苯二甲酸酯（42个实例，产率高达96％）。值得注意的是，仅使用1.0摩尔％的催化剂负载，表明高效率。后期精巧可提供高度功能化的类似物。
• NOVEL COMPOUNDS
  申请人：FARNABY William

  公开号：US20130052281A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（I）的化合物及其药用盐，其中R1和R2如规范中定义，以及它们的制备方法、含有它们的药物组合物以及它们在治疗中的用途。
• [EN] METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RÉCEPTEUR DE GLUTAMATE MÉTABOTROPIQUE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2012152854A1

  公开（公告）日：2012-11-15

  The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.

  该发明涉及杂环衍生物以及其药用可接受的盐。该发明还涉及制备这类化合物的方法。该发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病非常有用。
• Structure-Based Design of 3-(4-Aryl-1<i>H</i>-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y₁₄ Receptor Antagonists
  作者：Anna Junker、Ramachandran Balasubramanian、Antonella Ciancetta、Elisa Uliassi、Evgeny Kiselev、Chiara Martiriggiano、Kevin Trujillo、Giorgi Mtchedlidze、Leah Birdwell、Kyle A. Brown、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1021/acs.jmedchem.6b00044

  日期：2016.7.14

  UDP and UDP-glucose activate the P2Y14 receptor (P2Y14R) to modulate processes related to inflammation, diabetes, and asthma. A computational pipeline suggested alternatives to naphthalene of a previously reported P2Y14R antagonist (3, PPTN) using docking and molecular dynamics simulations on a hP2Y14R homology model based on P2Y12R structures. By reevaluating the binding of 3 to P2Y14R computationally

  UDP和UDP葡萄糖激活P2Y14受体（P2Y14R），以调节与炎症，糖尿病和哮喘有关的过程。计算流水线建议在基于P2Y12R结构的hP2Y14R同源性模型上使用对接和分子动力学模拟，以替代先前报道的P2Y14R拮抗剂（3，PPTN）中的萘。通过重新计算3与P2Y14R的结合，确定了两个替代方案，即炔基和三唑基衍生物。使用表达P2Y14R的CHO细胞的流式细胞术，可以改善荧光拮抗剂4的合成亲和力（IC50s，nM）。对-F 3 C-苯基-三唑65（32）比相应的炔烃11更有效。因此，在对接模拟的指导下，制备了额外的三唑基衍生物，其中偏极性芳基取代基受到青睐。尽管三唑的效力不及3（6），但更简单的合成促进了进一步的结构优化。另外，相对的P2Y14R亲和力与炔基和三唑类似物的预测结合一致。这些三唑是通过基于结构的方法设计的，可以在疾病模型中进行评估。